Multimeric peptide-based PEG nanocarriers with programmable elimination properties

Simi Gunaseelan, Shahriar Pooyan, Peiming Chen, Mahta Samizadeh, Matthew S. Palombo, Stanley Stein, Xiaoping Zhang, Patrick J. Sinko.

Department of Pharmaceutics, Rutgers University, NJ 08854, USA

UMDNJ-Rutgers CounterACT Research Center of Excellence, Rutgers University, Piscataway, NJ 08854, USA

**ABSTRACT**

In the current study, the design, synthetic feasibility and biochemical characterization of biodegradable peptidic PEG-based nanocarriers are described. The components were selected to influence the body elimination pathway upon nanocarrier biodegradation. Two prototypical nanocarriers were prepared using non-PEGylated and PEGylated peptidic cores \( \text{CH}_3 \text{CO-(Lys-Ala-Ala)-Cys-CONH}_2 \) \( X = 2, 4 \). A homodimeric nanocarrier with 4 copies of fluorescein-PEG5kDa was synthesized by linking two PEGylated peptidic cores \( X = 2 \) using a disulfide bond. A dual labeled heterodimeric nanocarrier with 2 copies of fluorescein-PEG5kDa and 4 copies of Texas Red was also synthesized. Optimum conditions for linking imaging agents, PEG, or a peptidic core to a peptidic core were determined. Significantly higher yields (69% versus 30%) of the PEGylated peptidic core were obtained by using 2 copies of \( \beta \)-alanine as a spacer along with increasing DMSO concentrations, which resulted in reduced steric hindrance. Stoichiometric addition of the components was also demonstrated and found to be important for reducing polydispersity. Nanocarrier biodegradation was evaluated in simulated intracellular and extracellular/blood environments using 3 mM and 10 mM glutathione in buffer, respectively. The nanocarrier was 9-fold more stable in the extracellular environment. The results suggest selective intracellular degradation of the nanocarrier into components with known body elimination pathways.

**ARTICLE INFO**

Article history:
Received 21 April 2009
Accepted 21 May 2009
Available online 31 July 2009

Keywords:
Peptide
PEG
Nanocarrier
Disulfide
GSH-dependent biodegradation
Intracellular elimination

1. Introduction

PEGylation, the process of conjugating proteins and other drugs to poly(ethylene glycol) (PEG), has improved the clinical performance of many drugs such as interferon \( \alpha-2a \) (PEGASYS\textsuperscript{®}) and interferon \( \alpha-2b \) (Peglntron\textsuperscript{®}) for treating diseases such as Hepatitis C infection and chronic myelogenous leukemia [1,2]. The observed improvements in clinical efficacy are primarily due to reduced proteolytic degradation, enhanced physical stability, higher solubility, and reduced systemic clearance due to a longer circulating half-life [3–5]. PEGylation results in reduced immunogenicity and antigenicity as well as reduced toxicity by, among other mechanisms, reducing interactions with the immune system such as dendritic cells and macrophages [6,7]. These are the very same cells that are infected by the Human Immunodeficiency Virus (HIV). Therefore, while PEGylation

has been enormously successful in maintaining plasma concentrations of various drugs, its utility as a targeting agent or drug delivery scaffold for eradicating HIV infection is low. Since many anti-HIV drugs have poor physicochemical and biopharmaceutical properties, our goal has been to design nanocarriers capable of delivering drugs specifically to HIV-infected cells while improving the solubility, stability and pharmacokinetics of these potent drugs.

Of the many advantages of PEGylation, the reduction in systemic clearance and prolonged body exposure to drugs is potentially one of the most important for AIDS patients since the “pill” burden (i.e., the number of dose units and frequency of administration) is high and patient compliance is far from ideal. PEGylation reduces renal clearance since the kidneys filter substances according to their size although charge, deformability and shape are also considered significant factors [8,9]. Since PEGylation results in a hydrophobic shift in physical properties, the rate of phagocytic elimination is also reduced [7,10–12]. For example, 12 copies of a 5 kDa PEG conjugated to bovine hemoglobin increased blood half-life by a factor of 14 and systemic availability by a factor of 8 [13,14]. In addition to reduced renal filtration, prolonged blood residence time was attributed to lower immunogenicity and reduced phagocytosis.
A comparative study in rats using rIL-2 modified to varying extents with PEGs of molecular weights ranging from 0.35 to 20 kDa showed that binding of several small PEGs (e.g., 350 Da) or one 4 kDa PEG did not alter their pharmacokinetics [15]. They also observed a rapid decrease in systemic clearance as the effective molecular size increased from 21 to approximately 70 kDa. This suggests progressive exclusion from glomerular filtration consistent with the general belief that molecules less than 20 kDa in size are well cleared by the kidneys. The clearance above 70 kDa was very low corresponding to the molecular weight of human serum albumin (~67 kDa), a protein that is predominantly excluded from filtration by the kidney glomerular basement membrane [15]. Due to its flexibility and deformability, it has been suggested that the optimal PEG mass for reduced renal clearance is ~40–60 kDa [16,17]. In the first phase of our studies, we developed a series of multi-arm and branched PEG nanocarriers containing multiple copies of the chemo-attractant peptide N-formyl-Met-Leu-Phe (fMLF) for the specific purpose of promoting macrophage uptake [18–20]. Maximal uptake in macrophage-like differentiated human U937 cells occurred at a scaffold size of 20 kDa whereas further increases in molecular weight up to 40 kDa resulted in lower uptake [20]. We observed similar results in vivo [19]. However, virtually no uptake was observed when fMLF was not present on the PEG nanocarrier consistent with reports of reduced interactions with macrophages due to PEG [6,7]. These results also support previous observations demonstrating that receptor-mediated endocytosis is strongly size dependent [21–24].

Polymer shape and branching are also known to alter the properties of PEG carriers [5,25–29]. For example, a branched PEG constructed of two linear molecules of succinimidyl carbonate PEG attached to the α- and ε- amino groups of lysine demonstrated higher proteolytic stability and a longer half-life in the blood as compared to their native and linear polymer conjugate counterparts [26,27]. The binding of a branched 10 kDa PEG to asparaginase reduced antigenicity by 10-fold as compared to the counterpart with a 5 kDa linear PEG [26,27]. It was also found to reduce uricase immunogenicity and antigenicity more efficiently than the linear 5 kDa polymer [30,31]. While the 10 kDa PEG2 is considerably smaller than the glomerular filtration threshold size, it was found to accumulate to a significant extent in the liver of Balb/c mice [30,31] suggesting that molecular shape and volume may be important factors in determining the biodistribution and clearance pathways of PEG nanocarriers.

There is considerable interest in determining the biological fate of soluble nanocarriers as well as other nano-sized carriers such as nanoparticles. In the present study, we shift our focus from the initial body distribution of nanocarriers (i.e., actively targeting HIV-infected cells) to designing nanocarriers with preprogrammed body elimination properties (i.e., nanocarriers that selectively release their cargo inside cells, degrade and follow a predetermined systemic elimination pathway).

2. Materials and methods

2.1. Materials


Fig. 1. Schematic representation of a monodisperse biodegradable dimeric nanocarrier composed of peptidic backbone irreversibly or reversibly conjugated with one or more targeting ligand/drug either directly or through the distal ends of PEG.
Cys(t-Butylthio)-β-Ala-Lys-β-Ala-Lys-β-Ala-Lys-β-Ala-Lys-β-Ala-Lys-β-Ala-Lys-Amidated MW 1627 Da were purchased from W.M. Keck Foundation Biotechnology Resource Laboratory (New Haven, CT). Fluorescein-PEG5kDa-NHS and m-PEG3.4kDa-NHS were purchased from Nektar Therapeutics Corp. (Huntsville, AL). Texas Red-NHS was obtained from Invitrogen (Eugene, OR). Sodium phosphate monobasic, sodium phosphate dibasic, tris buffer, dithiothreitol (DTT), 2,2'-dithiodipyridine (Aldrithiol-2; TP-TP), glutathione (GSH), ninhydrin, phenol, phenylalanine, potassium cyanide, trifluoroacetic acid (TFA) and dimethyl sulfoxide (DMSO) were purchased from Sigma–Aldrich Corp. (St. Louis, MO). Dimethylformamide (DMF) was purchased from Acros Organics (Morris Plains, NJ). Centrifugal filters (Amicon Ultra 30 kDa and Microcon 10 kDa) were obtained from Millipore Corp. (Billerica, MA). DIEA (N,N'-Diisopropylethylamine) was purchased from Acros Organics (Geel, Belgium).

2.2. Spectral analyses

UV spectra were recorded on a Beckman Coulter DU 640 spectrophotometer. Mass spectrometry using matrix-assisted-laser-desorption-ionization time-of-flight (MALDI-TOF) was performed on Voyager 4800. MALDI/MS data fully confirmed the structure of compounds.

2.3. Chromatography

Gel permeation chromatography was performed on a Sephadex G-75 (Amersham Bioscience; Uppsala, Sweden) using phosphate buffers (PB) pH 5.5 ± 0.2 and 7.4 ± 0.2 as eluents. The fluorescence readings of each fraction obtained from gel permeation chromatography were detected at $\lambda_{ex} = 485$ nm and $\lambda_{em} = 535$ nm (for fluorescein) using a Tecan GENios microplate reader (Durham, NC). Fluorescent compounds were also subjected to HPLC (Waters 2475 Multi λ Fluorescence Detector) using a size exclusion chromatographic column, TSKgel G4000PWx1, 7.8 mm × 30 cm, 10 μm (Tosoh Bioscience; Montgomery Ville, PA).

2.4. Quantification of peptidic cores

Nanocarriers were prepared using PEGylated and non-PEGylated peptidic cores (Figs. 1–3). The concentrations of free ε-amine groups of lysines on the peptidic cores were calculated using a quantitative Kaiser chromogenic assay established by Sarin et al. with modification [32]. The standard curve was first generated with phenylalanine. Ninhydrin solution (65 w/v) in ethanol was added to various concentrations of phenylalanine solution (14.5–60 nmol) dissolved in double distilled water, followed by the addition of phenol (4 g/ml) and potassium cyanide (0.65 mg/ml). The mixtures were heated at 110 °C for 2 min, followed by the addition of 2 ml of 60% ethanol. Optical density was read at 570 nm and a standard curve was prepared (Fig. 4). DMSO was used to dissolve the 2-arm peptide core (2 free amino groups on lysine) since it was sparingly soluble in water. The 4-arm peptide core (4 free amino groups on lysine) and 6-arm peptide core (6 free amino groups on lysine) were freely soluble in water. The concentrations of each of the peptidic cores were determined using the phenylalanine standard curve.

2.5. PEGylated 6-arm peptidic core

The PEGylation reaction of the peptidic core with 6 possible attachment sites (6-arm) at lysines was performed with 3 molar excess of m-PEG3.4 kDa-NHS. This reaction was carried out overnight using DMF:DIEA (99:1). The crude PEGylated 6-arm peptide core reaction was analyzed using MALDI-TOF (Fig. 5).

2.6. Fluorescein-labeled Cys-protected PEGylated 2-arm peptide core

The PEGylation reaction of the Cys-protected peptidic core with 2 possible attachment sites (2-arm) at lysine was performed with 3 molar excess of fluorescein-PEG5kDa-NHS dissolved in 30% or 70% (v:v) of DMSO in 100 mM PB pH 7.4 ± 0.2 (Fig. 2). The addition of activated PEG was performed over a period of one day.

![Fig. 2](image-url) Synthesis of homodimeric peptide-based PEG nanocarrier.
**Fig. 3.** Synthesis of heterodimeric peptide-based PEG nanocarrier.

1. **Cys-protected 2-arm peptidic core**
   - CH$_3$CO-Lys-$\beta$Ala-$\beta$Lys-$\beta$Ala-$\beta$Ala-Cys-CONH$_2$
   - NH$_2$
   - $\beta$Ala
   - TP
   - PEG-fl$^b$

2. **Fluorescein-labeled Cys-protected PEGylated 2-arm peptidic core**
   - CH$_3$CO-Lys-$\beta$Ala-$\beta$Ala-Lys-$\beta$Ala-$\beta$Ala-Cys-CONH$_2$
   - NH$_2$
   - $\beta$Ala
   - TP
   - PEG-fl$^b$
   - PEG-fl$^b$
   - SH

3. **Cys-protected 4-arm peptidic core**
   - CH$_3$CO-Lys-$\beta$Ala-$\beta$Ala-Cys-CONH$_2$
   - NH$_2$
   - $\beta$Ala
   - TP

4. **Texas Red-labeled Cys-protected 4-arm peptidic core**
   - CH$_3$CO-Lys-$\beta$Ala-$\beta$Ala-Cys-CONH$_2$
   - NH$_2$
   - $\beta$Ala
   - TP
   - Texas Red

5. **Fluorescein-labeled Cys-unprotected PEGylated 2-arm peptidic core**
   - CH$_3$CO-Lys-$\beta$Ala-$\beta$Ala-Lys-$\beta$Ala-$\beta$Ala-Cys-CONH$_2$
   - NH$_2$
   - $\beta$Ala
   - TP
   - PEG-fl$^b$
   - PEG-fl$^b$

6. **Dual-labeled heterodimeric peptide-based PEG nanocarrier**
   - CH$_3$CO-Lys-$\beta$Ala-$\beta$Ala-Lys-$\beta$Ala-$\beta$Ala-Cys-CONH$_2$
   - NH$_2$
   - $\beta$Ala
   - TP

---

$^a$ (i) 3 equiv of fluorescein-PEG5kDa-NHS in (a) 30% DMSO in 100 mM PB pH 7.4 (b) 70% DMSO in 100 mM PB pH 7.4
(ii) 20 equiv of DTT in 100 mM PB pH 8.0
(iii) 3 equiv of Texas Red-NHS in 30% DMSO in mM PB pH 7.4
(iv) mixing 4-arm TP-protected Cys with 2-arm free Cys in 100 mM PB pH 7.4

$^b$ = fluorescein
hour using four equal aliquots. The reaction was kept at room temperature for 16 h. Sephadex G-75 (medium) was soaked in PB pH 7.4 overnight and loaded onto a 50 cm Sephadex column. The PEGylated product was purified using gel permeation chromatography at a rate of approximately 0.8 ml/min. The fluorescence intensities of each fraction were detected using a microplate reader at $E_x = 485$ nm and $E_m = 535$ nm (Fig. 6). The first peak fractions for each chromatographic run were combined and concentrated using ultrafiltration (Amicon Ultra 30 kDa). The structure of the purified fluorescein-labeled PEGylated 2-arm peptidic core was confirmed using MALDI-TOF (Fig. 7).

2.7. Deprotection of fluorescein-labeled Cys-protected PEGylated 2-arm peptidic core

In order to remove thiopyridine from the Cys-protected PEGylated 2-arm peptidic core, it was dissolved in 20 molar equivalents of DTT in 100 mM PB at pH 8.0 ± 0.2 and left at room temperature for 2 h (Fig. 2). Unreacted DTT was removed using gel permeation chromatography on a Sephadex G-75 column in PB at pH 5.5 ± 0.2. The effluent was concentrated and washed with PB pH 7.4 ± 0.2 using a 10 kDa MWCO Microcon filter.

2.8. Fluorescein-labeled homodimeric peptide-based PEG nanocarrier

A fluorescein-PEG5kDa-NHS standard curve was used to correlate fluorescence to molar concentration of the synthesized fluorescein-labeled Cys-protected PEGylated 2-arm peptidic core and its unprotected counterpart. The PEGylated peptidic cores dissolved in 100 mM PB pH 7.4 ± 0.2 were mixed and reacted for 16 h at room temperature. The volume was reduced using ultrafiltration (Microcon 10 kDa MWCO) and dimerization (Fig. 2) was confirmed using size exclusion-HPLC (Fig. 8).

Fig. 4. Calibration curve of primary amine group of phenylalanine as a function of optical density (570 nm). This curve was obtained from quantitative Kaiser chromogenic assay. The concentration of primary amine groups on the 2-, 4- and 6-arm peptidic cores was determined using this chromogenic assay. All measurements were done in triplicate. ($R^2 = 0.993$).

Fig. 5. MALDI-TOF ($m/z$) spectrum of crude 6-arm PEGylated peptidic core reaction, showing the heterogeneity of products. The products contain a mixture of conjugation of 2 (7251 Da), 3 (11,082 Da), 4 (14,830 Da), 5 (18,261 Da) and 6 (21,773 Da) copies of m-PEG3.4kDa. (S. Gunaseelan et al. / Biomaterials 30 (2009) 5649–5659 5653)
In the current design, the free ε-amine groups of lysines on the 2-arm central peptide core [acetylated-Lys-βAla-βAla-Lys-βAla-βAla-Cys(TP)-amidated] and the 4-arm central peptide core [acetylated-Lys-βAla-βAla-Lys-βAla-Lys-βAla-βAla-βAla-Cys(TP)-amidated] are used for the attachment of fluorescein-PEG5kDa and Texas Red, respectively, (Figs. 2 and 3). Thus, it is necessary to quantify the amount of free amines present on the peptide cores prior to PEGylation or labeling. The most common method used for quantification of peptides having primary amines is based on fluorescamine, a heterocyclic dione reagent that reacts with primary amines to form a fluorescent product [36]. However, fluorescamine also reacts with water at lower rates and peptides/polypeptides tend to absorb moisture from the air. This side reaction often leads to inaccurate measurements. Therefore, a Kaiser

3. Results and discussion

It is widely believed that by treating only disease affected cells; drug dosages and side effects can be reduced, thus improving therapeutic outcomes. As such, drug targeting is an important goal in the treatment of AIDS or cancer since specific cell populations are involved in those diseases. To date, most targeting strategies have focused on controlling the initial distribution of delivery vehicles to the site of the disease. The most commonly used approach involves the selective delivery of drugs to specific cell types using a particulate carrier (e.g., liposomes or nanoparticles) or soluble nanocarriers (e.g., drug–polymer conjugates) with attached cell surface targeting ligands. The specificity of delivery is related to many factors including the type and number of targeting ligands required for optimal cellular uptake. Intracellular disposition and fate are highly dependent on the type of cell surface receptor and may require an additional strategy to promote endosomal escape. Previously, we developed first generation nanocarriers using the chemo-attractant peptide, N-formyl-Met-Leu-Phe (fMLF), which were capable of actively targeting macrophages in vitro and in vivo [18–20]. fMLF was selected as the first targeting ligand for the nanocarriers since the goal was to target macrophages, a phagocytic cell that plays a significant role in the persistence of HIV infection. We also recently showed that intracellular distribution could be controlled by using a Tat peptide to facilitate endosomal escape [35]. This is particularly important for drugs that are hydrophilic and act in the cytosol or must gain access to the nuclear compartment. We now shift our focus to the post-initial body distribution phase. In the current studies, second-generation multimeric peptide-backbone PEG nanocarriers (Figs. 1–3) were designed, synthesized, and characterized with the goal of building in specific body intracellular drug release and elimination properties. A biodegradable nanocarrier that is relatively stable in the blood circulation, while being selectively degraded inside target cells, was designed in order to exploit the natural extracellular–intracellular gradient of reducing conditions. The result is that the glutathione-sensitive disulfide bond between the monomeric peptide units of the nanocarrier is cleaved releasing components with known body elimination pathways.

3.1. PEGylation reaction of nanocarrier monomer

In the current design, the free ε-amine groups of lysines on the 2-arm central peptide core [acetylated-lys-βAla-βAla-lys-βAla-βAla-Cys(TP)-amidated] and the 4-arm central peptide core [acetylated-lys-βAla-βAla-lys-βAla-Lys-βAla-βAla-Lys-βAla-βAla-Cys(TP)-amidated] are used for the attachment of fluorescein-PEG5kDa and Texas Red, respectively, (Figs. 2 and 3). Thus, it is necessary to quantify the amount of free amines present on the peptide cores prior to PEGylation or labeling. The most common method used for quantification of peptides having primary amines is based on fluorescamine, a heterocyclic dione reagent that reacts with primary amines to form a fluorescent product [36]. However, fluorescamine also reacts with water at lower rates and peptides/polypeptides tend to absorb moisture from the air. This side reaction often leads to inaccurate measurements. Therefore, a Kaiser
chromogenic assay was selected over the conventional fluoresc-
amine assay in order to quantify the peptides used in the current
study. Since this assay is typically used to quantify primary amines
of peptides during solid phase synthesis [32], it was modified and
standardized for quantification of peptides in the liquid phase. The
assay was successfully adapted and a typical standard curve (Fig. 4)
demonstrated a strong correlation ($R^2 = 0.993$) between the
amount of primary amines in the 2- and 4-arm peptidic cores and
the released chromogenic product.

An inherent problem associated with PEGs is polydispersity.
This is particularly true at higher molecular weights [5,37]. A goal of
the current study was to design a nanocarrier with low
polydispersity and high yield. As size is a critical determinant of the
biodistribution and body persistence of nanocarriers, high
polydispersity is expected to lead to high bioavailability variability
and possibly to negative therapeutic outcomes. Lower molecular
weight PEGs (~3–5 kDa) have polydispersity values as low as 1.01
whereas they can be as high as 1.2 for larger molecular weight PEGs
(~20 kDa) [5,37]. Another complicating factor is the presence of the
impurity diol, which ranges from 1 to 15% depending on the
molecular weight of PEG. The diol content in low mass PEGs (~1%) is
much lower than that for higher molecular weight PEGs (~15%)
[5,37]. High diol concentrations lead to unwanted aggregates or
cross-linked products resulting in a low yield of the desired
product. Therefore, it was hypothesized that attaching multiple low
mass PEGs to the peptidic core would result in a higher yield of less
polydisperse PEG nanocarriers as compared to attaching a single
large PEG. Each PEG unit is attached in close proximity to each
other on the peptide backbone resembling a branched or comb
structure (Figs. 1–3). The PEGylated portion of the nanocarrier
resembles a branched PEG similar to PEG2, a second-generation
PEG [1,30,31]. Since branched PEGs have a relatively higher rate of
hydration as compared to their linear counterparts, the viscosity
radius of a protein that was PEGylated with four copies of a 5 kDa
PEG was equivalent to PEGylation with a single 20 kDa PEG [38].
This also appears to hold true for the pharmacokinetics of
PEGylated proteins. For example, Knauf et al. [15] demonstrated
that the systemic clearance and elimination half-life of
recombinant interleukin-2 that was PEGylated with multiple
smaller PEGs or one larger PEG was essentially the same in rats.
Taken together, these results suggest that the final topology and
effective size of the nanocarrier are what determines biological
functionality.

Achieving complete PEGylation of all of the ε-amine moieties on
the peptidic core was challenging. As demonstrated by MALDI-TOF
analysis, the initial PEGylation of a 6 lysine peptidic core where
each lysine was separated by only one copy of β-alanine resulted in
heterogeneous products containing 2–6 copies of 3.4 kDa PEG
(Fig. 5). It was hypothesized that due to the close proximity of
lysine, the PEGylation reaction was hindered. This was addressed
by designing a peptidic core consisting of 4 internal lysines (i.e., a
4-arm central peptidic core) with two β-alanine residues repeated
after each lysine moiety in order to provide adequate spacing. This
spacing was found to be favorable for entry and conjugation of

Fig. 7. MALDI-TOF (m/z) spectrum of purified labeled Cys-protected fully PEGylated 2-arm peptidic core. The peak showing molecular weight of 11,099.0 Da confirms attachments of two fluorescein-PEG5kDa to the 2-arm peptidic core.
Fig. 8. HPLC chromatogram of purified Cys-protected PEGylated 2-arm peptidic core (A, C), crude homodimeric peptide-based PEG nanocarrier (E) and crude homodimeric nanocarrier spiked with purified Cys-protected PEGylated 2-arm peptidic core (B, D, F). Different flow rates have been used to obtain better resolution. Spiking was performed to confirm the formation of the homodimeric nanocarrier and for better visualization.
a large diameter (5 kDa) hydrated activated PEG. However, the analytical Kaiser assay indicated that only 50% of the total ε-amines reacted. This represented a significant improvement over the 30% PEGylation observed with the single β-alanine spacer in the peptidic core. However, total PEG content was still low considering that the target molecular size of the nanocarrier should ideally be between 20 kDa and 40 kDa. This issue was addressed by designing a peptidic core with 2 lysine PEG attachment sites and increasing PEG content by dimerizing the purified 2-arm PEGylated product (Fig. 2). The purification of the PEGylated product using a G-75 Sephadex column is shown in Fig. 6. When the fluorescein-PEG5kDa-NHS polymer was loaded by itself onto the column a single peak was obtained. The higher mobility peak corresponds to the 'fully' PEGylated product and the lower mobility peak represents a combination of excess unreacted fluorescein-PEG5kDa-NHS and 'partially' PEGylated peptidic core (Fig. 6). The mass of the higher mobility PEGylated product was determined by MALDI-TOF (Fig. 7). The expected molecular weight very closely matched the theoretical value confirming the formation of the PEGylated product (Fig. 2). Each ethylene glycol subunit is associated with two or three water molecules that impart a high hydrodynamic volume to the PEG resulting in a 5–10-fold increase in effective size. Higher DMSO concentrations (70%) resulted in a high PEGylated product yield (69%) whereas the low DMSO conditions resulted in a much lower yield of 32%. It appears that high aqueous conditions (i.e., low DMSO concentrations) lead to higher hydrodynamic volume and high steric hindrance resulting in dramatically reduced PEGylation product yield. Conversely, increasing the DMSO concentration resulted in an environment where PEG is not fully hydrated, steric hindrance is reduced and a higher PEGylated product yield is obtained. Therefore, higher concentrations of DMSO along with 2 copies of β-alanine spacer are crucial for successful PEGylation of peptidic core.

3.2. Homodimerization of peptide-based PEG nanocarrier

The presence of cysteine in the peptidic core enables the production of a dimeric second-generation nanocarrier. By using the multimter approach, the body elimination pathway can be precisely programmed into the nanocarrier design. This is achieved by controlling the degree of branching and the size of the monomers. The current design did not specifically include the cleavage of the monomer to its peptide and PEG components since the peptide did not contribute significantly to the overall size and the monomer size is below the renal filtration threshold. The homodimeric nanocarrier consisted of two monomers of a PEGylated 2-arm peptidic core monomer carrying 2 copies of fluorescein-PEG5kDa linked via a disulfide bond (Fig. 2). This design resulted in a nanocarrier with a MW of 21,950 Da. By reacting an equimolar amount of purified thiopyridine protected PEGylated 2-arm peptidic core with its unprotected counterpart, homodimerization was achieved (Fig. 2). The purified Cys-protected PEGylated 2-arm peptidic core generated single peaks at retention times of ~7 and ~11 min at flow rates of 0.7 and 0.5 ml/min.
respectively, using size exclusion-HPLC (Fig. 8; Panels A and C). At flow rate of 0.3 ml/min, the crude homodimerization product exhibited an obvious shoulder with slower mobility (Fig. 8, Panel E). In order to further resolve the product, the crude product was spiked with purified Cys-protected PEGylated 2-arm peptidic core (Fig. 8; Panel F) at the same flow rate. This addition proved to be crucial for visualization of the dimerized product. At flow rates of 0.5 and 0.7 ml/min the homodimerized product was observed as a distinct shoulder with slower mobility (Fig. 8; Panels B and D) when spiked with free PEGylated 2-arm peptidic core. The flow rate of 0.3 ml/min gave the best resolution with minimal absorptive loss.

3.3. Heterodimeric peptide-based PEG nanocarrier and its biodegradation characteristics

A dual labeled heterodimeric nanocarrier consisting of a PEGylated 2-arm peptidic core monomer carrying two copies of fluorescein-PEG5kDa and a non-PEGylated 4-arm peptidic core monomer carrying ~four copies of Texas Red linked via a disulfide bond was prepared for the purposes of assessing its potential for biodegradation (Fig. 3). The purified heterodimeric nanocarrier was subjected to MALDI-TOF mass spectrometry (Fig. 9). The obtained mass exhibited an increase to 13,375 Da consistent with the expected increase in molecular weight confirming the presence of the product. The biodegradation of the nanocarrier was investigated in environments that mimic the reducing concentration in blood (10 μM GSH) or inside cells (3 mM GSH) [39,40]. The reduction of the disulfide linkage and subsequent release of the nanocarrier monomers was monitored at each time-point by stopping the reaction using an acidifying solution. The small 4-arm peptidic core monomer carrying Texas Red passed through a 10 kDa MWCO filter while the free fluorescein-PEGylated 2-arm peptidic core is retained on the filter. Thus, simulated biodegradation was monitored by the reduction in the Texas Red fluorescence signal. The Texas Red fluorescence signal in the retentate is attributed to the intact heterodimeric nanocarrier. Biodegradation in the presence of 3 mM GSH at 37 °C resulted in complete release of the Texas Red-labeled 4-arm monomer from the intact heterodimeric nanocarrier in 7 min (Fig. 10). When the solution containing the heterodimer was modified to a final concentration of 1% TFA prior to the addition of GSH, release was not observed and the values were nearly identical to the zero time-point even after 2 h of incubation at 37 °C. This demonstrates that acidifying the solution stopped the reaction thus allowing for proper temporal quantification of biodegradation. In addition, the fluorescein tag remained attached to terminal end of PEG during the study as evidenced by a lack of signal at Ex = 485 nm; Em = 535 nm from the filtrate. Therefore, at conditions that mimic the reducing environment inside the cell, the heterodimeric nanocarrier showed complete degradation to its monomeric components. Upon incubation of the doubly labeled nanocarrier in 10 μM GSH, biodegradation to its component monomers was complete after 60 min (Fig. 11). Prolonged incubation or addition of excess GSH (3 mM for one hour) did not further reduce the fluorescence reading. Since the oxidation and loss of GSH during the time course of the study was not observed, the stabilization method was considered valid. Although the nanocarrier was stable for ~1 h in a reducing environment similar to the blood, the target blood stability is probably in the range of 24 h or so in order to provide adequate exposure of the nanocarrier to affected cells. Our group and others have shown that the rate of biodegradation of the disulfide linkage can be manipulated by altering steric hindrance [34,41,42]. For example, a disulfide bond prepared from a sterically hindered cysteamine analogue linker, 1-amino-2-methyl-2-propanethiol, showed about 100-times slower degradation rate than that of the corresponding less hindered cysteamine linker (t1/2 of GSH-dependent disulfide degradation = 3 min) [34]. The introduction of sterically hindered methyl groups to the peptidic core adjacent to the cysteine residue may result in a longer persistence for intact nanocarrier. Since the disulfide cleavage rate is proportional to glutathione concentration [42], the rate of biodegradation can be readily controlled by selection of such sterically hindered cysteines in the peptidic backbone of the nanocarrier prior to disulfide bond formation. In addition to the use of disulfide bonds, more stable carbamate or ester linkages can also be used to prolong the biodegradation rate.

4. Conclusions

In the current studies, a second-generation peptidic core monomer was identified that allowed for optimal attachment of multiple PEGs in stoichiometric amounts with low polydispersity.
High product yields were obtained by selecting the optimal spacing requirements in the peptide core and by using high concentrations of DMSO to reduce the hydrodynamic volume of solvated PEG. Homodimeric and heterodimeric biodegradable nanocarriers were synthesized and characterized from PEGylated and non-PEGylated peptide cores. Selective intracellular biodegradation was observed in vitro. The modular synthesis of these nanocarriers has the advantage of minimizing polydispersity, a challenge that is always present with polymeric nanocarriers. The design is sufficiently flexible so that the component peptide monomers could be used to link PEGs, imaging agents, drugs, targeting ligands or other peptidic cores. Two important design components, the biodegradable bonds between monomeric peptidic core units and using PEGs of the appropriate size in order to promote renal or hepatic elimination, allows for the pre-programming of body elimination properties into the nanocarrier.

Acknowledgements

Partial financial support from NIH AI51214 and the Parke-Davis Endowed Chair in Pharmaceutics and Drug Delivery is gratefully acknowledged. A fellowship from the American Foundation for Pharmaceutical Education to Matthew Palombo is also acknowledged.

References